Yuhan 미래 성장

Future 기준 확인 3/6

Yuhan (는) 각각 연간 21.9% 및 9.3% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 20.9% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 9.8% 로 예상됩니다.

주요 정보

21.9%

수익 성장률

20.9%

EPS 성장률

Pharmaceuticals 수익 성장	31.8%
매출 성장률	9.3%
향후 자기자본 수익률	9.8%
애널리스트 커버리지	Good
마지막 업데이트	16 Nov 2024

최근 미래 성장 업데이트

Recent updates

Yuhan Corporation (KRX:000100) May Have Run Too Fast Too Soon With Recent 25% Price Plummet

Nov 14

Is Yuhan (KRX:000100) Using Too Much Debt?

Oct 08

Estimating The Intrinsic Value Of Yuhan Corporation (KRX:000100)

Sep 16

Subdued Growth No Barrier To Yuhan Corporation (KRX:000100) With Shares Advancing 41%

Aug 28

Yuhan Corporation's (KRX:000100) Price In Tune With Earnings

Jul 01

Yuhan Corporation (KRX:000100) Shares Could Be 37% Below Their Intrinsic Value Estimate

Jun 13

Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

May 26

Here's Why Yuhan (KRX:000100) Can Manage Its Debt Responsibly

May 13

Yuhan Corporation's (KRX:000100) P/E Is Still On The Mark Following 26% Share Price Bounce

Mar 11

Yuhan (KRX:000100) Has A Pretty Healthy Balance Sheet

May 01

Are Investors Undervaluing Yuhan Corporation (KRX:000100) By 32%?

Apr 16

Should You Or Shouldn't You: A Dividend Analysis on Yuhan Corporation (KRX:000100)

Mar 15

Are Yuhan Corporation's (KRX:000100) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Feb 25

Is There More To The Story Than Yuhan's (KRX:000100) Earnings Growth?

Feb 10

Does Yuhan (KRX:000100) Have A Healthy Balance Sheet?

Jan 28

The Yuhan (KRX:000100) Share Price Has Gained 92% And Shareholders Are Hoping For More

Jan 13

Has Yuhan Corporation's (KRX:000100) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Nov 20

수익 및 매출 성장 예측

KOSE:A000100 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (KRW Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	2,485,917	244,105	253,780	259,346	16
12/31/2025	2,283,485	195,043	217,405	222,300	16
12/31/2024	2,095,987	136,015	91,122	161,831	11
9/30/2024	2,008,841	165,686	-93,593	59,730	N/A
6/30/2024	1,893,119	147,849	-75,289	100,417	N/A
3/31/2024	1,860,529	124,466	-80,670	110,014	N/A
12/31/2023	1,858,984	133,993	-59,775	144,128	N/A
9/30/2023	1,872,336	88,109	-59,302	113,301	N/A
6/30/2023	1,820,811	76,045	-94,824	48,972	N/A
3/31/2023	1,808,041	101,446	-18,662	106,905	N/A
12/31/2022	1,775,847	95,144	-2,356	99,529	N/A
9/30/2022	1,749,315	74,669	21,500	112,004	N/A
6/30/2022	1,769,245	97,836	64,662	146,027	N/A
3/31/2022	1,719,630	97,911	-77,146	1,983	N/A
12/31/2021	1,687,810	102,583	17,726	99,000	N/A
9/30/2021	1,725,261	98,128	-40,214	63,556	N/A
6/30/2021	1,703,475	97,833	-90,028	16,218	N/A
3/31/2021	1,685,623	97,578	33,086	125,628	N/A
12/31/2020	1,619,865	192,761	-55,854	28,830	N/A
9/30/2020	1,552,188	184,730	-12,076	40,572	N/A
6/30/2020	1,504,765	168,667	95,017	136,587	N/A
3/31/2020	1,448,677	140,227	-32,349	12,995	N/A
12/31/2019	1,480,354	40,006	19,251	65,985	N/A
9/30/2019	1,500,782	44,230	22,262	71,414	N/A
6/30/2019	1,497,130	41,438	-43,955	1,332	N/A
3/31/2019	1,523,954	52,333	109,427	156,727	N/A
12/31/2018	1,518,823	57,481	45,602	93,452	N/A
9/30/2018	1,481,906	70,146	54,109	108,573	N/A
6/30/2018	1,482,034	84,572	N/A	107,587	N/A
3/31/2018	1,450,870	100,288	N/A	112,160	N/A
12/31/2017	1,462,248	109,034	N/A	126,125	N/A
9/30/2017	1,434,749	139,325	N/A	116,234	N/A
6/30/2017	1,417,835	137,434	N/A	135,085	N/A
3/31/2017	1,395,518	139,440	N/A	142,224	N/A
12/31/2016	1,320,797	161,249	N/A	74,144	N/A
9/30/2016	1,274,011	134,997	N/A	98,827	N/A
6/30/2016	1,223,925	155,819	N/A	97,292	N/A
3/31/2016	1,163,130	152,682	N/A	88,684	N/A
12/31/2015	1,128,731	126,047	N/A	126,235	N/A
9/30/2015	1,097,229	118,104	N/A	120,389	N/A
6/30/2015	1,046,716	98,362	N/A	140,058	N/A
3/31/2015	1,031,875	94,628	N/A	71,402	N/A
12/31/2014	1,017,492	90,948	N/A	94,386	N/A
9/30/2014	1,007,109	95,434	N/A	78,642	N/A
6/30/2014	970,253	87,696	N/A	44,515	N/A
3/31/2014	953,191	83,863	N/A	56,486	N/A
12/31/2013	943,609	86,461	N/A	79,778	N/A

애널리스트 미래 성장 예측

수입 대 저축률: A000100 의 연간 예상 수익 증가율( 21.9% )이 saving rate( 2.7% 보다 높습니다. ).

수익 vs 시장: A000100 의 연간 수익( 21.9% ) KR 시장( 29.3% 보다 느리게 성장할 것으로 예상됩니다. 29.3% 연간).

고성장 수익: A000100 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: A000100 의 수익(연간 9.3% ) KR 시장( 9.2% 보다 빠르게 성장할 것으로 예상됩니다. 9.2% 연간).

고성장 수익: A000100 의 수익(연간 9.3% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: A000100 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 9.8 %).

Yuhan 미래 성장

Future 기준 확인 3/6

주요 정보

최근 미래 성장 업데이트

Price target increased by 8.1% to ₩110,188

Price target increased by 7.9% to ₩108,412

Price target increased by 7.1% to ₩99,222

Consensus revenue estimates increase by 28%

Consensus EPS estimates increase by 37%, revenue downgraded

Price target increased by 7.8% to ₩80,222

Recent updates

Dividend of ₩429 announced

Yuhan Corporation (KRX:000100) May Have Run Too Fast Too Soon With Recent 25% Price Plummet

Is Yuhan (KRX:000100) Using Too Much Debt?

Price target increased by 8.1% to ₩110,188

Price target increased by 7.9% to ₩108,412

Investor sentiment improves as stock rises 17%

Estimating The Intrinsic Value Of Yuhan Corporation (KRX:000100)

Investor sentiment improves as stock rises 44%

Subdued Growth No Barrier To Yuhan Corporation (KRX:000100) With Shares Advancing 41%

Price target increased by 7.1% to ₩99,222

Investor sentiment deteriorates as stock falls 15%

Now 20% undervalued

Investor sentiment improves as stock rises 15%

Yuhan Corporation's (KRX:000100) Price In Tune With Earnings

Yuhan Corporation (KRX:000100) Shares Could Be 37% Below Their Intrinsic Value Estimate

Investor sentiment improves as stock rises 19%

Yuhan's (KRX:000100) Earnings Are Weaker Than They Seem

Consensus revenue estimates increase by 28%

Here's Why Yuhan (KRX:000100) Can Manage Its Debt Responsibly

Now 22% overvalued after recent price rise

Full year 2023 earnings released: EPS: ₩1,815 (vs ₩1,267 in FY 2022)

Yuhan Corporation's (KRX:000100) P/E Is Still On The Mark Following 26% Share Price Bounce

Investor sentiment improves as stock rises 18%

Insufficient new directors

Now 21% undervalued

Upcoming dividend of ₩381 per share at 0.6% yield

Consensus EPS estimates increase by 37%, revenue downgraded

Investor sentiment deteriorates as stock falls 23%

Now 24% undervalued

Price target increased by 7.8% to ₩80,222

First quarter 2023 earnings released: EPS: ₩311 (vs ₩222 in 1Q 2022)

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Now 21% undervalued after recent price drop

Upcoming dividend of ₩381 per share

Consensus EPS estimates fall by 11%

Now 20% undervalued

Full year 2021 earnings: EPS and revenues miss analyst expectations

Yuhan Corporation (KOSE:A000100) announces an Equity Buyback for KRW 20,000 million worth of its shares.

Upcoming dividend of ₩381 per share

Third quarter 2021 earnings released: EPS ₩470 (vs ₩464 in 3Q 2020)

First quarter 2021 earnings released: EPS ₩315 (vs ₩1,768 in 1Q 2020)

Yuhan (KRX:000100) Has A Pretty Healthy Balance Sheet

Consensus forecasts updated

Are Investors Undervaluing Yuhan Corporation (KRX:000100) By 32%?

Should You Or Shouldn't You: A Dividend Analysis on Yuhan Corporation (KRX:000100)

Full year 2020 earnings released: EPS ₩2,943 (vs ₩610 in FY 2019)

New 90-day low: ₩60,700

Are Yuhan Corporation's (KRX:000100) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?

Yuhan Corporation, Annual General Meeting, Mar 19, 2021

Is There More To The Story Than Yuhan's (KRX:000100) Earnings Growth?

Does Yuhan (KRX:000100) Have A Healthy Balance Sheet?

The Yuhan (KRX:000100) Share Price Has Gained 92% And Shareholders Are Hoping For More

New 90-day high: ₩75,100

Is Yuhan Corporation (KRX:000100) Popular Amongst Institutions?

New 90-day high: ₩75,100

Estimating The Fair Value Of Yuhan Corporation (KRX:000100)

New 90-day high: ₩72,300

Is Yuhan Corporation's (KRX:000100) 0.6% Dividend Worth Your Time?

Has Yuhan Corporation's (KRX:000100) Impressive Stock Performance Got Anything to Do With Its Fundamentals?

Price target raised to ₩72,704

Price target raised to ₩67,579

Yuhan Corporation and Sorrento Therapeutics, Inc. Announces Completion of Phase 1 Clinical Study of Anti-PD-L1 Antibody IMC-001

New 90-day high: ₩72,000

Price target raised to ₩63,148

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견